Clinical Trial: NCT03336333 - My Cancer Genome

NCT03336333

Description:

This study will enroll subjects with previously untreated CLL/SLL into two cohorts (Cohort 1 without del[17p] and Cohort 2 with del[17p]). Cohort 1 subjects will receive either "BGB-3111 alone" or "bendamustine (B) and rituximab (R)". Cohort 2 subjects will receive BGB-3111 alone. The primary purpose is to evaluate the efficacy and safety of BGB-3111 versus bendamustine and rituximab in Cohort 1.

Related Conditions:

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting Status:

Recruiting

Phase:

Phase 3

URL:

https://clinicaltrials.gov/show/NCT03336333

Trial Eligibility

Document

Title

Brief Title: A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Official Title: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Clinical Trial IDs

ORG STUDY ID: BGB-3111-304
NCT ID: NCT03336333

Conditions

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Interventions

Drug	Synonyms	Arms
BGB-3111		BGB-3111 (patients without del[17p])
Bendamustine	Treanda, Ribomustin, and Levact	B+R
Rituximab	Rituxan, MabThera	B+R

Purpose

Detailed Description

      This is a global phase 3, open label, randomized study of BGB-3111 versus bendamustine plus
      rituximab (B+R) in subjects with previously untreated chronic lymphocytic leukemia or small
      lymphocytic lymphoma (CLL/SLL), including subjects without del(17p) [Cohort 1] and subjects
      with del(17p) [Cohort 2]. Subjects in Cohort 1 are randomized 1:1 to BGB-3111 (Arm A) or
      bendamustine plus rituximab (Arm B). Randomization will be stratified by age, Binet stage,
      immunoglobulin variable region heavy chain (IGHV) mutational status, and geographic region.
      Subjects in Cohort 2 receive treatment with BGB-3111.

Trial Arms

Name	Type	Description	Interventions
BGB-3111 (patients without del[17p])	Experimental	Approximately 210 subjects in Cohort 1 to receive BGB-3111	BGB-3111
B+R	Experimental	Approximately 210 subjects in Cohort 1 to receive bendamustine plus rituximab	Bendamustine Rituximab
BGB-3111 patients with del[17p])	Experimental	Approximately 47 subjects in Cohort 2 to receive BGB-3111	BGB-3111

Eligibility Criteria

        Inclusion Criteria: All subjects

          1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator.

          2. Confirmed diagnosis of CD20-positive CLL or SLL.

          3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment.

          4. ECOG performance status of 0, 1 or 2.

          5. Life expectancy ≥ 6 months.

          6. Adequate bone marrow function.

          7. Adequate renal and hepatic function.

          8. Females of childbearing potential and non-sterile males must agree to use highly
             effective methods of birth control throughout the course of study

          9. Male patients are eligible if vasectomized or if they agree to use of barrier
             contraception with other methods described above throughout the course of study.

         10. Written informed consent.

        Exclusion Criteria: All subjects

          1. Previous systemic treatment for CLL/SLL.

          2. Known prolymphocytic leukemia or history of or suspected Richter's transformation.

          3. Clinically significant cardiovascular disease.

          4. Prior malignancy within the past 3 years, except for curatively treated basal or
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
             cervix of breast.

          5. Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.

          6. History of severe bleeding disorder.

          7. History of stroke or intracranial hemorrhage within 6 months before the first dose of
             study drug.

          8. Severe or debilitating pulmonary disease.

          9. Inability to swallow capsules or disease affecting gastrointestinal function.

         10. Known central nervous system involvement by leukemia or lymphoma.

         11. Active infection requiring systemic treatment.

         12. Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
             infection.

         13. Vaccination with live vaccine within 35 days prior to the first dose of study drug.

         14. Known hypersensitivity to BGB-3111, bendamustine, or rituximab or any other
             ingredients of the study drugs.

         15. Requires ongoing treatment with strong CYP3A inhibitor or inducer.

         16. Pregnant or nursing females.

         17. Concurrent participation in another therapeutic clinical trial.

Maximum Eligible Age:	N/A
Minimum Eligible Age:	18 Years
Eligible Gender:	All
Healthy Volunteers:	No

Primary Outcome Measures

Measure:	Progression-free survival between treatment groups in Cohort 1 (BGB-3111 vs. bendamustine plus rituximab) as determined by independent central review
Time Frame:	From randomization to the date of first documentation of disease progression or death, whichever occurs first, assessed up to 5 years.
Safety Issue:
Description:

Secondary Outcome Measures

Measure:	Overall response rate between treatment groups in Cohort 1 as determined by independent central review and by investigator assessment.
Time Frame:	From time of best response recorded from randomization until data cut or start of new anticancer treatment, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Overall survival between treatment groups in Cohort 1
Time Frame:	From time of randomization until date of death due to any reason, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Duration of response between treatment groups in Cohort 1 determined by independent central review and by investigator assessment
Time Frame:	From date that response criteria are first met to the date of first documentation of disease progression or death, whichever occurs first, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Progression-free survival between treatment groups in Cohort 1 determined by investigator assessment
Time Frame:	From randomization to the date of first documentation of disease progression or death, whichever occurs first, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Overall response rate in Cohort 2 as determined in independent central review
Time Frame:	From time of best response recorded from randomization until data cut or start of new anticancer treatment, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Overall survival in Cohort 2
Time Frame:	From time of first BGB-3111 dose administration until date of death due to any reason, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Progression-free survival in Cohort 2 determined by independent central review
Time Frame:	From the date of first BGB-3111 dose administration to the date of first documentation of disease progression or death, whichever occurs first, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Duration of response in Cohort 2 determined by independent central review
Time Frame:	From date that response criteria are first met to the date of first documentation of disease progression or death whichever occurs first, assessed up to 5 years.
Safety Issue:
Description:

Measure:	Incidence, nature and severity of adverse events between treatment groups in Cohort 1
Time Frame:	From date of first study drug dose to approximately 30 days after end of treatment
Safety Issue:
Description:

Details

Phase:	Phase 3
Primary Purpose:	Interventional
Overall Status:	Recruiting
Lead Sponsor:	BeiGene

Trial Keywords

BGB-3111
BTK inhibitor
bendamustine
rituximab
Phase 3

Last Updated

November 7, 2017

Clinical Trials /

A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL